Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice

Psychosomatic Medicine

Volumn 74, Issue 1, 2012, Pages 63-72

  Isingrini, Elsa ^a   Belzung, Catherine ^a   Freslon, Jean Louis ^a   MacHet, Marie Christine ^a   Camus, Vincent ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

atherosclerosis; depression; endothelial dysfunction; endothelium derived factors; model of chronic stress; vasodilatation

Indexed keywords

ACETYLCHOLINE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLUOXETINE; NITRIC OXIDE; PROSTACYCLIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BAGG ALBINO MOUSE; BLOOD VESSEL REACTIVITY; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNPREDICTABLE CHRONIC MILD STRESS; VASCULAR RING; VASODILATATION;

EID: 84855700817     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e31823a43e0     Document Type: Article

References (56)

1. Camus V, Kraehenbuhl H, Preisig M, Bula CJ, Waeber G. Geriatric depression and vascular diseases: what are the links? J Affect Disord 2004; 81:1-16. (Pubitemid 38759321)
2. Lesperance F, Frasure-Smith N. Depression and heart disease. Cleve Clin J Med 2007;74(suppl 1):S63-6.
3. Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med 2005;67(suppl 1):S19-25. (Pubitemid 40721027)
4. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-15. (Pubitemid 38668397)
5. Lippi G, Montagnana M, Favaloro EJ, Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 2009;35:325-36.
6. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009;12:1-21.
7. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002;105:546-9. (Pubitemid 34123425)
8. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288: 373-6. (Pubitemid 11169009)
9. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-18. (Pubitemid 19187609)
10. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 2006;26:1215-25. (Pubitemid 44305364)
11. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc 1979;38:66-71. (Pubitemid 9084965)
12. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005;20:547-51. (Pubitemid 41565341)
13. Needleman P, Bronson SD, Wyche A, Sivakoff M, Nicolaou KC. Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest 1978;61:839-49.
14. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-49.
15. Hecker M. Endothelium-derived hyperpolarizing factorVfact or fiction? News Physiol Sci 2000;15:1-5.
16. Isingrini E, Desmidt T, Belzung C, Camus V. Endothelial dysfunction: a potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease? Curr Opin Investig Drugs 2009;10:46-55.
17. Broadley AJ, Korszun A, Abdelaal E, Moskvina V, Deanfield J, Jones CJ. Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol 2006;48:170-5. (Pubitemid 44202475)
18. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol 2005;46:656-9. (Pubitemid 41132693)
19. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry 2006;60:889-91. (Pubitemid 44527889)
20. Faramawi MF, Gustat J, Wildman RP, Rice J, Johnson E, Sherwin R. Relation between depressive symptoms and common carotid artery atherosclerosis in American persons 9 or =65 years of age. Am J Cardiol 2007; 99:1610-3. (Pubitemid 46770645)
21. Chrapko WE, Jurasz P, RadomskiMW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004;56:129-34. (Pubitemid 38844788)
22. Willner P. Chronic mild stress (CMS) revisited: consistency and behaviouralneurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110. (Pubitemid 41160326)
23. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9. (Pubitemid 36962615)
24. Pothion S, Bizot JC, Trovero F, Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 2004;155:135-46. (Pubitemid 39119974)
25. Mineur YS, Belzung C, Crusio WE. Functional implications of decreases in neurogenesis following chronic mild stress in mice. Neuroscience 2007;150:251-9. (Pubitemid 350198721)
26. d'Audiffret AC, Frisbee SJ, Stapleton PA, Goodwill AG, Isingrini E, Frisbee JC. Depressive behavior and vascular dysfunction: a link between clinical depression and vascular disease? J Appl Physiol 2010;108:1041-51.
27. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2010;125:241-8.
28. Matthews KA, Chang YF, Sutton-Tyrrell K, Edmundowicz D, Bromberger JT. Recurrent major depression predicts progression of coronary calcification in healthy women: Study of Women's Health Across the Nation. Psychosom Med 2010;72:742-7.
29. Surget A, Belzung C. Unpredictable chronic mild stress in mice. In: Kalueff AV, LaPorte JL, editors. Experimental Models in Neurobehavioral Research. New York, NY: Nova Science; 2008:79-112.
30. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008;64: 293-301.
31. Yalcin I, Belzung C, Surget A. Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav Brain Res 2008;193:140-3.
32. Isingrini E, Camus V, Le Guisquet AM, Pingaud M, Devers S, Belzung C. Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 2010;5:e10404.
33. Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav Pharmacol 2007; 18:623-31. (Pubitemid 47524888)
34. Ibarguen-Vargas Y, Surget A, Vourc'h P, Leman S, Andres CR, Gardier AM. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009;202:245-51.
35. Mineur YS, Belzung C, Crusio WE. Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav Brain Res 2006;175:43-50. (Pubitemid 44691920)
36. D'Aquila PS, Brain P, Willner P. Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression. Physiol Behav 1994;56:861-7. (Pubitemid 24337098)
37. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134:319-29. (Pubitemid 28023396)
38. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol 2002;13:169-88. (Pubitemid 34816463)
39. Neves VJ, Moura MJ, Tamascia ML, Ferreira R, Silva NS, Costa R. Proatherosclerotic effects of chronic stress in male rats: altered phenylephrine sensitivity and nitric oxide synthase activity of aorta and circulating lipids. Stress 2009;12:320-7.
40. Le Melledo JM, Mahil N, Baker GB. Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder? J Psychiatry Neurosci 2004;29:414-6. (Pubitemid 40075712)
41. Lara N, Archer SL, Baker GB, Le Melledo JM. Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol 2003;23:641-5. (Pubitemid 37443193)
42. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009;86:527-32.
43. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C. Role of EDHF in Type 2 diabetesYinduced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;295:H1982-8.
44. Edwards G, Feletou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 2010;459: 863-79.
45. Ni W, Thompson JM, Northcott CA, Lookingland K, Watts SW. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 2004;43:770-81. (Pubitemid 38679598)
46. Ramage AG, Villalon CM. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008;29:472-81.
47. Vanhoutte PM, Scott-Burden T. The endothelium in health and disease. Tex Heart Inst J 1994;21:62-7. (Pubitemid 24111393)
48. McDuffie JE, Coaxum SD, Maleque MA. 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proc Soc Exp Biol Med 1999;221:386-90.
49. Richardson SM, Maleque MA, Motley ED. 3-Morpholinosyndnonimine inhibits 5-hydroxytryptamine-induced phosphorylation of nitric oxide synthase in endothelial cells. Cell Mol Biol (Noisy-le-grand) 2003;49: 1385-9.
50. Blardi P, De Lalla A, Leo A, Auteri A, Iapichino S, Di Muro A. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002;22:131-6. (Pubitemid 34289387)
51. Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006;31:1286-93. (Pubitemid 43971844)
52. Ungvari Z, Pacher P, Koller A. Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol 2000;35:849-54. (Pubitemid 30327512)
53. van Melle JP, Buikema H, van den Berg MP, van Buiten A, van Veldhuisen DJ, Boonstra PW. Sertraline causes strong coronary vasodilation: possible relevance for cardioprotection by selective serotonin reuptake inhibitors. Cardiovasc Drugs Ther 2004;18:441-7. (Pubitemid 40487022)
54. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-34. (Pubitemid 20226996)
55. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
56. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990;10:316-23. (Pubitemid 20103595)